A first-in-human phase I study of a novel MDM2/p53 inhibitor alrizomadlin in advanced solid tumors.
Zhang X, Wen X, Peng R, Pan Q, Weng D, Ma Y, Zhang Y, Yang J, Men L, Wang H, Liang E, Wang C, Yang D, Zhang L, Zhai Y.
Zhang X, et al.
ESMO Open. 2024 Aug;9(8):103636. doi: 10.1016/j.esmoop.2024.103636. Epub 2024 Jul 13.
ESMO Open. 2024.
PMID: 39002360
Free PMC article.
Clinical Trial.